• News

FDA expands Pfizer’s Talzenna-Xtandi label to hormone-sensitive prostate cancer

pharminent October 27, 2026

• News

Roche’s divarasib beats approved KRAS G12C drugs in NSCLC trial

pharminent October 26, 2026

• News

Moderna and Merck’s melanoma vaccine cuts recurrence risk 42%

pharminent October 23, 2026

• News

FDA approves GSK’s hepatitis B drug Hibsago licensed from Ionis

pharminent October 22, 2026

• News

Novo’s CagriSema shows 25% weight loss in women in late-stage analysis

pharminent October 21, 2026

• News

AstraZeneca and Oracle launch AI platform for clinical trials

pharminent October 20, 2026

• News

FDA approves Viatris’ Ryzumvi for adult presbyopia

pharminent October 19, 2026

• News

AstraZeneca and insitro sign cardiometabolic AI deal worth up to $1.5B

pharminent October 16, 2026

• News

Ultragenyx raises $413M from two priority review voucher sales

pharminent October 15, 2026

• News

J&J raises 2026 guidance as Tremfya drives third-quarter immunology sales

pharminent October 14, 2026

• News

Roche licenses Rona’s RNAi obesity program in $1B deal

pharminent October 13, 2026

• News

FDA approves Asahi Kasei’s Hovilpri for refractory HSV lesions

pharminent October 12, 2026

• News

Viatris to acquire Pacira in $1.7B pain drug deal

pharminent October 9, 2026

• News

FDA approves Pfizer’s Tukysa combination for metastatic breast cancer

pharminent October 8, 2026

• News

AbbVie and Genmab’s Epkinly succeeds in frontline DLBCL trial

pharminent October 7, 2026

• News

Shionogi to acquire IntraBio for $2B in rare disease deal

pharminent October 6, 2026

• News

FDA approves Lilly’s Jaypirca for first-line CLL and SLL

pharminent October 5, 2026

• News

Novartis signs $7.8B Abogen deal for autoimmune T-cell engager

pharminent October 2, 2026

• News

Sanofi and Regeneron expand immunology alliance in $8B deal

pharminent October 1, 2026

• News

Novo to pay Hengrui up to $2.6B for once-weekly obesity pill

pharminent September 30, 2026

• News

AstraZeneca takes 10% Summit stake in $2B deal

pharminent September 29, 2026

• News

FDA approves AbbVie’s Parkinson’s disease therapy Juvmo

pharminent September 28, 2026

• News

FDA advisers back Grail’s multicancer detection blood test

pharminent September 25, 2026

• News

FDA approves Lilly’s once-weekly basal insulin Onswik for type 2 diabetes

pharminent September 24, 2026

• News

Amgen’s dazodalibep meets goals in phase 3 Sjögren’s trial

pharminent September 23, 2026

• News

FDA approves Lilly’s breast cancer combination treatment

pharminent September 22, 2026

• News

Telix to acquire ITM in deal worth up to $2.35B

pharminent September 21, 2026

• News

FDA approves Ultragenyx’s gene therapy Fayuvi for Sanfilippo syndrome type A

pharminent September 18, 2026

• News

NICE Clears Enhertu in HER2-Low Breast Cancer After England Raised Its Cost-Effectiveness Threshold

pharminent September 17, 2026

• News

Novartis Drops ALS for Lifonebart After Astrals Misses Every Endpoint — but Keeps the Molecule in Alzheimer’s

pharminent September 16, 2026

• News

GSK Licenses a Preclinical Trispecific T Cell Engager From China’s Chimagen for Up to $750M in Myeloma

pharminent September 15, 2026

• News

Scholar Rock’s Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning

pharminent September 14, 2026

• Commercial

Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand

pharminent September 14, 2026

• Regulatory

Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval

pharminent September 14, 2026

• Regulatory

Psychedelic therapies ride wave of public favor into FDA hearing

pharminent September 14, 2026

• News

FDA Oncology Chief Sets Out His Agenda — and Narrows the Etcamah Precedent

pharminent September 11, 2026

• Manufacturing

Samsung Biologics inks $262M manufacturing deal with European pharma company

pharminent September 11, 2026

• M&A / Deals

Exegenesis Bio and Modalis sign research deal for Duchenne therapy

pharminent September 11, 2026

• News

Bayer’s Hyrnuo Wins Accelerated Frontline Approval in HER2-Mutant NSCLC, Seven Months Behind Boehringer

pharminent September 10, 2026

• Regulatory

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

pharminent September 10, 2026